TABLE OF CONTENTS
1 INTRODUCTION 60
1.1 OBJECTIVES OF THE STUDY 60
1.2 MARKET DEFINITION 60
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET 60
1.4 LIMITATIONS 62
1.5 MARKETS COVERED 62
2 MARKET SEGMENTATION 66
2.1 MARKETS COVERED 66
2.2 GEOGRAPHICAL SCOPE 67
2.3 YEARS CONSIDERED FOR THE STUDY 68
2.4 CURRENCY AND PRICING 68
2.5 DBMR TRIPOD DATA VALIDATION MODEL 69
2.6 MULTIVARIATE MODELLING 72
2.7 PRODUCT TYPE LIFELINE CURVE 72
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 73
2.9 DBMR MARKET POSITION GRID 74
2.10 MARKET TESTING TYPE COVERAGE GRID 75
2.11 VENDOR SHARE ANALYSIS 76
2.12 SECONDARY SOURCES 77
2.13 ASSUMPTIONS 77
3 EXECUTIVE SUMMARY 78
4 PREMIUM INSIGHTS 81
4.1 PESTEL ANALYSIS 82
4.2 PORTERS FIVE FORCES 83
5 INDUSTRY INSIGHTS: 84
6 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, REGULATION 85
7 MARKET OVERVIEW 87
7.1 DRIVERS 89
7.1.1 GROWING DEMAND FOR NON-INVASIVE LIQUID BIOPSY TECHNIQUE 89
7.1.2 ADVANCEMENTS IN PRECISION MEDICINE DUE TO LIQUID BIOPSY 90
7.1.3 INCREASING CANCER PREVALENCE AND AWARENESS 91
7.1.4 TECHNOLOGICAL ADVANCEMENTS IN LIQUID BIOPSY PLATFORMS 92
7.2 RESTRAINTS 93
7.2.1 HIGH COST OF LIQUID BIOPSY TESTS 93
7.2.2 LACK OF STANDARDIZED GUIDELINES 94
7.3 OPPORTUNITIES 95
7.3.1 INTEGRATION OF ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING 95
7.3.2 INCREASING REIMBURSEMENTS AND GOVERNMENT SUPPORT FOR LIQUID BIOPSY 96
7.3.3 INCREASING R&D ACTIVITIES BY INSTITUTES 96
7.4 CHALLENGES 97
7.4.1 LACK OF SKILLED PROFESSIONALS PERFORMING LIQUID BIOPSY 97
7.4.2 INCREASED DEPENDENCY ON OTHER BIOPSIES 98
8 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY PRODUCT 99
8.1 OVERVIEW 100
8.2 CONSUMABLES & ACCESSORIES 103
8.2.1 TEST KITS 104
8.2.1.1 TOTAL NUCLEIC ACID ISOLATION KIT 104
8.2.1.2 DNA ISOLATION KIT 104
8.2.1.3 OTHERS 104
8.2.2 COLLECTION TUBES 104
8.2.2.1 50 PIECES 105
8.2.2.2 100 PIECES 105
8.2.3 ASSAYS 105
8.2.3.1 FLEXIBLE REAGENTS 105
8.2.3.2 SCALABLE REAGENTS 105
8.2.3.3 OTHERS 105
8.2.4 CONTROL KIT 105
8.2.5 OTHERS 105
8.3 INSTRUMENTS 105
8.3.1 ANALYZERS 106
8.3.2 SYSTEMS 106
8.3.3 OTHERS 107
8.4 SERVICES & SOFTWARE 107
8.4.1 NGS ANALYSIS AND REPORTING SOFTWARE 108
8.4.2 DPCR ANALYSIS SOFTWARE 108
8.4.3 CASTPCR ANALYSIS SOFTWARE 108
8.4.4 OTHERS 108
9 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE 109
9.1 OVERVIEW 110
9.2 CIRCULATING TUMOR CELLS (CTCS) 113
9.3 CIRCULATING CELL-FREE DNA (CFDNA) 114
9.4 CELL-FREE RNA 115
9.5 EXOSOMES 116
9.6 EXTRACELLULAR VESICLES 117
9.7 OTHERS 118
10 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY SAMPLE TYPE 119
10.1 OVERVIEW 120
10.2 BLOOD SAMPLE-BASED 123
10.3 URINE SAMPLE-BASED 124
10.4 SALIVA & OTHER TISSUE FLUIDS SAMPLE-BASED 125
10.5 OTHERS 126
11 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE 127
11.1 OVERVIEW 128
11.2 MOLECULAR 131
11.2.1 NGS 132
11.2.2 PCR 132
11.2.3 MICROARRAY 132
11.2.4 PROTEOMICS 132
11.2.5 OTHERS 132
11.3 PROTEOMIC 132
11.3.1 NGS 133
11.3.2 PCR 133
11.3.3 MICROARRAY 133
11.3.4 PROTEOMICS 133
11.3.5 OTHERS 133
11.4 HISTOLOGY/IMAGING 134
12 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY APPLICATION TYPE 135
12.1 OVERVIEW 136
12.2 CANCER APPLICATIONS 139
12.2.1 LUNG 140
12.2.2 BREAST 140
12.2.2.1 EARLY BREAST CANCER 140
12.2.2.2 ADVANCED BREAST CANCER 140
12.2.3 COLORECTAL 140
12.2.4 PROSTRATE 141
12.2.5 LIVER 141
12.2.6 OTHERS 141
12.3 NON-CANCER APPLICATIONS 141
12.3.1 PRENATAL DIAGNOSIS 142
12.3.2 PERSONALIZED IMMUNOTHERAPY 142
12.3.3 OTHERS 142
13 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION 143
13.1 OVERVIEW 144
13.2 ROUTINE SCREENING 147
13.3 THERAPY SELECTION 148
13.4 TREATMENT MONITORING 148
13.4.1 EARLY-STAGE DISEASE 149
13.4.2 LATE-STAGE/METASTATIC DISEASE 149
13.5 RECURRENCE MONITORING 150
13.6 PATIENT WORK-UP 150
13.7 OTHERS 151
14 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY TECHNOLOGY 152
14.1 OVERVIEW 153
14.2 MULTI-GENE-PARALLEL ANALYSIS 156
14.3 SINGLE GENE ANALYSIS 157
15 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY END USER 158
15.1 OVERVIEW 159
15.2 HOSPITALS 162
15.3 REFERENCE LABORATORIES 162
15.4 DIAGNOSTIC CENTERS 163
15.5 RESEARCH CENTERS AND ACADEMIC INSTITUTES 163
15.6 OTHERS 165
16 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL 166
16.1 OVERVIEW 167
16.2 DIRECT TENDER 170
16.3 THIRD PARTY DISTRIBUTOR 170
16.4 OTHERS 171
17 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, BY REGION 172
17.1 MIDDLE EAST AND AFRICA 173
17.1.1 SOUTH AFRICA 185
17.1.2 SAUDI ARABIA 192
17.1.3 U.A.E. 199
17.1.4 EGYPT 206
17.1.5 ISRAEL 213
17.1.6 REST OF MIDDLE EAST AND AFRICA 220
18 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET, COMPANY LANDSCAPE 221
18.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 221
19 COMPANY PROFILE 222
19.1 F. HOFFMANN-LA ROCHE LTD. 222
19.1.1 COMPANY SNAPSHOT 222
19.1.2 REVENUE ANALYSIS 222
19.1.3 COMPANY SHARE ANALYSIS 223
19.1.4 PRODUCT PORTFOLIO 223
19.1.5 RECENT DEVELOPMENTS 223
19.2 GUARDANT HEALTH 224
19.2.1 COMPANY SNAPSHOT 224
19.2.2 REVENUE ANALYSIS 224
19.2.3 COMPANY SHARE ANALYSIS 225
19.2.4 PRODUCT PORTFOLIO 225
19.2.5 RECENT DEVELOPMENTS 225
19.3 THERMO FISHER SCIENTIFIC INC. 226
19.3.1 COMPANY SNAPSHOT 226
19.3.2 REVENUE ANALYSIS 226
19.3.3 COMPANY SHARE ANALYSIS 227
19.3.4 SWOT ANALYSIS 227
19.3.5 PRODUCT PORTFOLIO 228
19.3.6 RECENT DEVELOPMENTS 229
19.4 EXACT SCIENCE CORPORATION 230
19.4.1 COMPANY SNAPSHOT 230
19.4.2 REVENUE ANALYSIS 230
19.4.3 COMPANY SHARE ANALYSIS 231
19.4.4 PRODUCT PORTFOLIO 231
19.4.5 RECENT DEVELOPMENTS 231
19.5 QIAGEN 232
19.5.1 COMPANY SNAPSHOT 232
19.5.2 REVENUE ANALYSIS 232
19.5.3 COMPANY SHARE ANALYSIS 233
19.5.4 PRODUCT PORTFOLIO 233
19.5.5 RECENT DEVELOPMENTS 234
19.6 ANGLE PLC (2022) 235
19.6.1 COMPANY SNAPSHOT 235
19.6.2 REVENUE ANALYSIS 235
19.6.3 PRODUCT PORTFOLIO 236
19.6.4 RECENT DEVELOPMENT 236
19.7 BIOCEPT, INC. 237
19.7.1 COMPANY SNAPSHOT 237
19.7.2 REVENUE ANALYSIS 237
19.7.3 PRODUCT PORTFOLIO 238
19.7.4 RECENT DEVELOPMENT 238
19.8 BIO-RAD LABORATORIES, INC. (2022) 239
19.8.1 COMPANY SNAPSHOT 239
19.8.2 REVENUE ANALYSIS 239
19.8.3 PRODUCT PORTFOLIO 240
19.8.4 RECENT DEVELOPMENTS 240
19.9 EPIC SCIENCES 241
19.9.1 COMPANY SNAPSHOT 241
19.9.2 PRODUCT PORTFOLIO 241
19.9.3 RECENT DEVELOPMENTS 241
19.10 FLUXION BIOSCIENCES INC 242
19.10.1 COMPANY SNAPSHOT 242
19.10.2 PRODUCT PORTFOLIO 242
19.10.3 RECENT DEVELOPMENTS 242
19.11 ILLUMINA, INC. 243
19.11.1 COMPANY SNAPSHOT 243
19.11.2 REVENUE ANALYSIS 243
19.11.3 SWOT ANALYSIS 244
19.11.4 PRODUCT PORTFOLIO 244
19.11.5 RECENT DEVELOPMENT 244
19.12 JOHNSON & JOHNSON PRIVATE LIMITED 246
19.12.1 COMPANY SNAPSHOT 246
19.12.2 REVENUE ANALYSIS 246
19.12.3 SWOT ANALYSIS 247
19.12.4 PRODUCT PORTFOLIO 247
19.12.5 RECENT DEVELOPMENTS 247
19.13 LABORATORY CORPORATION OF AMERICA HOLDINGS 248
19.13.1 COMPANY SNAPSHOT 248
19.13.2 REVENUE ANALYSIS 248
19.13.3 SWOT ANALYSIS 249
19.13.4 PRODUCT PORTFOLIO 249
19.13.5 RECENT DEVELOPMENT 249
19.14 MDXHEALTH 250
19.14.1 COMPANY SNAPSHOT 250
19.14.2 REVENUE ANALYSIS 250
19.14.3 PRODUCT PORTFOLIO 251
19.14.4 RECENT DEVELOPMENTS 251
19.15 MENARINI SILICON BIOSYSTEMS 252
19.15.1 COMPANY SNAPSHOT 252
19.15.2 PRODUCT PORTFOLIO 252
19.15.3 RECENT DEVELOPMENTS 252
19.16 NATERA, INC. 253
19.16.1 COMPANY SNAPSHOT 253
19.16.2 REVENUE ANALYSIS 253
19.16.3 PRODUCT PORTFOLIO 254
19.16.4 RECENT DEVELOPMENTS 254
19.17 NEOGENOMICS LABORATORIES 255
19.17.1 COMPANY SNAPSHOT 255
19.17.2 REVENUE ANALYSIS 255
19.17.3 PRODUCT PORTFOLIO 256
19.17.4 RECENT DEVELOPMENTS 256
19.18 ONCOCYTE CORPORATION 257
19.18.1 COMPANY PROFILE 257
19.18.2 SERVICE PORTFOLIO 257
19.18.3 RECENT DEVELOPMENTS 257
19.19 PATHAI 258
19.19.1 COMPANY SNAPSHOT 258
19.19.2 PRODUCT PORTFOLIO 258
19.19.3 RECENT DEVELOPMENTS 258

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.